Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology—From Bench to Bedside
Tryptophan (Trp)-based radiotracers have excellent potential for imaging many different types of brain pathology because of their involvement with both the serotonergic and kynurenine (KYN) pathways. However, radiotracers specific to the kynurenine metabolism pathway are limited. In addition, histor...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/15/1/47 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588904220327936 |
|---|---|
| author | Erik Stauff Wenqi Xu Heidi H. Kecskemethy Sigrid A. Langhans Vinay V. R. Kandula Lauren W. Averill Xuyi Yue |
| author_facet | Erik Stauff Wenqi Xu Heidi H. Kecskemethy Sigrid A. Langhans Vinay V. R. Kandula Lauren W. Averill Xuyi Yue |
| author_sort | Erik Stauff |
| collection | DOAJ |
| description | Tryptophan (Trp)-based radiotracers have excellent potential for imaging many different types of brain pathology because of their involvement with both the serotonergic and kynurenine (KYN) pathways. However, radiotracers specific to the kynurenine metabolism pathway are limited. In addition, historically Trp-based radiopharmaceuticals were synthesized with the short-lived isotope carbon-11. A newer generation of Trp-based imaging agents using the longer half-lived and commercially available isotopes, such as fluorine-18 and iodine-124, are being developed. The newly developed amino acid-based tracers have been demonstrated to have favorable radiochemical and imaging characteristics in pre-clinical studies. However, many barriers still exist in the clinical translation of KYN pathway-specific radiotracers. |
| format | Article |
| id | doaj-art-65e1230a684b4440b1cd125517bf0f42 |
| institution | Kabale University |
| issn | 2218-273X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj-art-65e1230a684b4440b1cd125517bf0f422025-01-24T13:24:58ZengMDPI AGBiomolecules2218-273X2025-01-011514710.3390/biom15010047Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology—From Bench to BedsideErik Stauff0Wenqi Xu1Heidi H. Kecskemethy2Sigrid A. Langhans3Vinay V. R. Kandula4Lauren W. Averill5Xuyi Yue6Department of Radiology, Nemours Children’s Health, Delaware, Wilmington, DE 19803, USADepartment of Radiology, Nemours Children’s Health, Delaware, Wilmington, DE 19803, USADepartment of Radiology, Nemours Children’s Health, Delaware, Wilmington, DE 19803, USADiagnostic & Research PET/MR Center, Nemours Children’s Health, Delaware, Wilmington, DE 19803, USADepartment of Radiology, Nemours Children’s Health, Delaware, Wilmington, DE 19803, USADepartment of Radiology, Nemours Children’s Health, Delaware, Wilmington, DE 19803, USADepartment of Radiology, Nemours Children’s Health, Delaware, Wilmington, DE 19803, USATryptophan (Trp)-based radiotracers have excellent potential for imaging many different types of brain pathology because of their involvement with both the serotonergic and kynurenine (KYN) pathways. However, radiotracers specific to the kynurenine metabolism pathway are limited. In addition, historically Trp-based radiopharmaceuticals were synthesized with the short-lived isotope carbon-11. A newer generation of Trp-based imaging agents using the longer half-lived and commercially available isotopes, such as fluorine-18 and iodine-124, are being developed. The newly developed amino acid-based tracers have been demonstrated to have favorable radiochemical and imaging characteristics in pre-clinical studies. However, many barriers still exist in the clinical translation of KYN pathway-specific radiotracers.https://www.mdpi.com/2218-273X/15/1/47tryptophankynurenine pathwayradiopharmaceuticalPETbrain imagingclinical translation |
| spellingShingle | Erik Stauff Wenqi Xu Heidi H. Kecskemethy Sigrid A. Langhans Vinay V. R. Kandula Lauren W. Averill Xuyi Yue Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology—From Bench to Bedside Biomolecules tryptophan kynurenine pathway radiopharmaceutical PET brain imaging clinical translation |
| title | Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology—From Bench to Bedside |
| title_full | Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology—From Bench to Bedside |
| title_fullStr | Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology—From Bench to Bedside |
| title_full_unstemmed | Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology—From Bench to Bedside |
| title_short | Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology—From Bench to Bedside |
| title_sort | tryptophan kynurenine pathway based imaging agents for brain disorders and oncology from bench to bedside |
| topic | tryptophan kynurenine pathway radiopharmaceutical PET brain imaging clinical translation |
| url | https://www.mdpi.com/2218-273X/15/1/47 |
| work_keys_str_mv | AT erikstauff tryptophankynureninepathwaybasedimagingagentsforbraindisordersandoncologyfrombenchtobedside AT wenqixu tryptophankynureninepathwaybasedimagingagentsforbraindisordersandoncologyfrombenchtobedside AT heidihkecskemethy tryptophankynureninepathwaybasedimagingagentsforbraindisordersandoncologyfrombenchtobedside AT sigridalanghans tryptophankynureninepathwaybasedimagingagentsforbraindisordersandoncologyfrombenchtobedside AT vinayvrkandula tryptophankynureninepathwaybasedimagingagentsforbraindisordersandoncologyfrombenchtobedside AT laurenwaverill tryptophankynureninepathwaybasedimagingagentsforbraindisordersandoncologyfrombenchtobedside AT xuyiyue tryptophankynureninepathwaybasedimagingagentsforbraindisordersandoncologyfrombenchtobedside |